192 related articles for article (PubMed ID: 36879087)
1. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS
Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gefapixant, a P2X
McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA;
Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186
[TBL] [Abstract][Full Text] [Related]
3. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
[TBL] [Abstract][Full Text] [Related]
4. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
Kum E; Patel M; Diab N; Wahab M; Zeraatkar D; Chu DK; O'Byrne PM; Guyatt GH; Satia I
JAMA; 2023 Oct; 330(14):1359-1369. PubMed ID: 37694849
[TBL] [Abstract][Full Text] [Related]
6. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
Smith JA; Birring SS; Dicpinigaitis PV; McGarvey LP; Morice AH; Pavord ID; Satia I; Green S; Iskold B; La Rosa C; Li Q; Martin Nguyen A; Schelfhout J; Muccino D
Lung; 2022 Aug; 200(4):423-429. PubMed ID: 35895098
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.
Nussbaum J; Hussain A; Ford A; Butera P; Kitt M; Smith S; Stoch A; Iwamoto M
Lung; 2022 Jun; 200(3):315-323. PubMed ID: 35670873
[TBL] [Abstract][Full Text] [Related]
8. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial.
Smith JA; Kitt MM; Bell A; Noulin N; Tzontcheva A; Seng MM; Lu S
Pulm Ther; 2022 Sep; 8(3):297-310. PubMed ID: 35969360
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial.
Martinez FJ; Afzal AS; Smith JA; Ford AP; Li JJ; Li Y; Kitt MM;
Pulm Ther; 2021 Dec; 7(2):471-486. PubMed ID: 34152585
[TBL] [Abstract][Full Text] [Related]
11. Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
Muccino DR; Morice AH; Birring SS; Dicpinigaitis PV; Pavord ID; Assaid C; Kleijn HJ; Hussain A; La Rosa C; McGarvey L; Smith JA
ERJ Open Res; 2020 Oct; 6(4):. PubMed ID: 33263037
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
Morice AH; Birring SS; Smith JA; McGarvey LP; Schelfhout J; Martin Nguyen A; Xu ZJ; Wu WC; Muccino DR; Sher MR
Lung; 2021 Apr; 199(2):121-129. PubMed ID: 33825965
[TBL] [Abstract][Full Text] [Related]
13. Gefapixant in two randomised dose-escalation studies in chronic cough.
Smith JA; Kitt MM; Butera P; Smith SA; Li Y; Xu ZJ; Holt K; Sen S; Sher MR; Ford AP
Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31949115
[TBL] [Abstract][Full Text] [Related]
14. Randomised trial of the P2X
Niimi A; Saito J; Kamei T; Shinkai M; Ishihara H; Machida M; Miyazaki S
Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34649978
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough.
McGarvey L; Smith JA; Morice A; Birring SS; Chung KF; Dicpinigaitis PV; Niimi A; Benninger MS; Sher M; Matsunaga Y; Miyazaki S; Machida M; Ishihara H; Mahmood A; Gomez JC
Lung; 2023 Feb; 201(1):25-35. PubMed ID: 36512069
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis.
Zheng Z; Huang J; Xiang Z; Wu T; Lan X; Xie S; Lin Z; Tang K; Morice A; Li S; Song WJ; Chen R
EClinicalMedicine; 2023 Aug; 62():102100. PubMed ID: 37538538
[TBL] [Abstract][Full Text] [Related]
17. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
[TBL] [Abstract][Full Text] [Related]
18. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
Morice A; Smith JA; McGarvey L; Birring SS; Parker SM; Turner A; Hummel T; Gashaw I; Fels L; Klein S; Francke K; Friedrich C
Eur Respir J; 2021 Nov; 58(5):. PubMed ID: 33986030
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials.
Abu-Zaid A; Aljaili AK; Althaqib A; Adem F; Alhalal DA; Almubarak AF; Aldughaither SM; Alghabban SA; Alfaraj G; Masoud AT; Alsuhaibani NA
Ann Thorac Med; 2021; 16(2):127-140. PubMed ID: 34012479
[TBL] [Abstract][Full Text] [Related]
20. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
Muccino D; Green S
Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
